Nebivolol Stada

Nebivolol, the active ingredient in Nebivolol Stada, is a β1‑selective beta‑blocker presented as an oral tablet for oral use. It treats hypertension and, when indicated, heart failure in adult patients.

GNH USA supplies Nebivolol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nebivolol is indicated for cardiovascular conditions, primarily hypertension and heart failure. - Hypertension: lowers blood pressure by reducing heart rate and peripheral vascular resistance. - Heart failure (when indicated): improves cardiac output and reduces symptoms in patients with reduced ejection fraction. - Left ventricular dysfunction: contributes to better ventricular performance as part of heart‑failure management.

Nebivolol may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Dizziness - Headache - Fatigue - Bradycardia - Nausea - Peripheral edema

Serious or Rare Side Effects: - Severe bradycardia - Marked hypotension - Bronchospasm in patients with reactive airway disease - Atrioventricular block - Allergic reactions such as rash or angioedema - Hepatic dysfunction

When prescribing Nebivolol, clinicians should consider several safety measures. - Blood pressure monitoring: ensure adequate control without excessive hypotension. - Cardiac function assessment: evaluate for bradyarrhythmias before initiation. - Respiratory caution: avoid in patients with severe asthma or COPD. - Concomitant beta‑blockers: do not combine with other β‑blockers without specialist advice. - Renal/hepatic impairment: dose adjustment may be required in moderate to severe dysfunction. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Nebivolol can interact with other medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other beta‑blockers: additive negative chronotropic effects. - Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): may raise nebivolol plasma levels. - Clonidine abrupt withdrawal: can precipitate severe hypertension. - Non‑selective beta‑blockers: heightened bradycardia risk.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - ACE inhibitors/ARBs: watch for additive hypotensive effect. - NSAIDs: may reduce antihypertensive efficacy. - Anti‑arrhythmic agents: potential for conduction disturbances. - Antidiabetic drugs: nebivolol may mask hypoglycaemic symptoms.